You are now leaving GSK’s website

This link will take you to a non-GSK website. GSK does not recommend, endorse or accept liability for sites controlled by third-parties.

Continue

Go back

Formulary support

The documents below have been designed to support commissioners and healthcare professionals when making a Trelegy Ellipta formulary application.

Trelegy Ellipta evidence summary

The Trelegy Ellipta evidence summary provides licensing information, clinical, financial and environmental data. This has been designed to support commissioners and healthcare professionals when making a Trelegy Ellipta formulary application and/or deciding positioning within a local guideline.

To download a PDF copy of the evidence summary, click on the image of the document.

Trelegy Ellipta evidence dossier

The Trelegy Ellipta evidence dossier contains additional clinical and graphical information to accompany the evidence summary. This has been designed to support commissioners and healthcare professionals when making a Trelegy Ellipta formulary application and/or deciding positioning within a local guideline.

To download a PDF copy of the evidence dossier, click on the image of the document.

Trelegy Ellipta is part of the Ellipta range of COPD maintenance medicines. Formulary support for the other Ellipta medicines is available in the Respiratory formulary support section.

Innoviva logo

Trelegy and Ellipta are registered trademarks of the GlaxoSmithKline group of companies